IP Library Granted Patent US 9,226,890
Granted Patent B1
US 9,226,890 · App. 14/564,369 · Granted Jan 5, 2016

Polysilicone base for scar treatment

Inventors: Julio Lamberty (Hawthorne, NJ); Yi-Chun Lin (Hackensack, NJ)
Assignee: ENGLEWOOD LAB, LLC
A61K8/891A61K8/25A61K8/89A61Q19/00A61Q19/08A61K2800/594
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,226,890
App. No.
14/564,369
Granted
Jan 5, 2016
Kind
B1
Abstract

A polysilicone base for medical and cosmetic compositions includes a dimethicone fluid, a volatile cyclosiloxane, a silicone elastomer, and nanoparticulate silica. The polysilicone base may also include one or more therapeutic agents for reducing the formation and appearance of scar tissue at the site of a wound. The polysilicone base is spreadable, but does not run off of the wound site. The polysilicone base is phase-stable, in that it does not separate into phases.

Claims (8)

1. A polysilicone base for medical and cosmetic compositions, comprising:

a first dimethicone fluid having a viscosity of about 100 cSt, said first dimethicone fluid being present in the base in an amount in the range of from about 23% to about 35% by weight;

a second dimethicone fluid having a viscosity of about 1,000 cSt, said second dimethicone fluid being present in said base in an amount in the range of from about 2% to about 5% by weight;

a third dimethicone fluid having a viscosity of about 60,000 cSt, said third dimethicone fluid being present in said base in an amount in the range of from about 1% to about 5% by weight;

a volatile cyclopentasiloxane fluid present in said base in an amount in the range of from about 32% to about 49% by weight;

a stearoxymethicone/dimethicone copolymer present in said base in an amount in the range of from about 23% to about 35% by weight; and

a nanoparticulate silica present in said base in an amount in the range of from about 0.4% to about 0.8% by weight, wherein at least said first and second dimethicones and said volatile cyclopentasiloxane are of types recognized in the medical arts as medical grade materials.

2. The polysilicone base of claim 1 , further comprising at least one therapeutic agent for reducing the formation and/or appearance of scar tissue at a site of a wound.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Mar 6, 2025
From: JPMORGAN CHASE BANK, N.A.
To: ENGLEWOOD LAB, INC.
Reel/Frame 070429/0115 →
SECURITY INTEREST Recorded Jan 10, 2020
From: ENGLEWOOD LAB, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 051474/0796 →
MERGER AND CHANGE OF NAME Recorded Dec 16, 2019
From: ENGLEWOOD LAB, LLC; ENGLEWOOD LAB, INC.
To: ENGLEWOOD LAB, INC.
Reel/Frame 051298/0402 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 18, 2015
From: LAMBERTY, JULIO; LIN, YI-CHUN
To: ENGLEWOOD LAB, LLC
Reel/Frame 037071/0920 →
Continuity (2)
Provisional Application 62028915 · Jul 25, 2014
Provisional Application 61914168 · Dec 10, 2013